FDA approved two emergency INDs for COVID-19 outpatient therapy
On Aug. 6, 2020, Organicell Regenerative Medicine announced that the FDA had approved two outpatient Emergency Investigational New Drug Applications for treating mild to moderate respiratory distress due to COVID-19.
Tags:
Source: Organicell Regenerative Medicine
Credit:
